All successful Phase III combinations employed concurrent checkpoint blockade during chemotherapy (not sequential approaches), proving particularly critical in HR+ breast cancer, where chemotherapy-induced immune activation requires immediate checkpoint inhibitor presence, preventing rapid PD-1/PD-L1-mediated suppression. The gene discussed is CD274; the disease is breast cancer.